Aurobindo Pharma receives 6 observations after inspection of Aurobindo Pharma Jedcherla plant.
The United States Food and Drug Administration (US FDA) inspected Aurobindo Pharma's Unit VII, an oral manufacturing facility situated at Jedcherla, Hyderabad, from 2nd to 10th May 2022.
An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
The FDA Form 483 notifies the company’s management of objectionable conditions. At the conclusion of an inspection, the FDA Form 483 is presented and discussed with the company’s senior management. Companies are encouraged to respond to the FDA Form 483 in writing with their corrective action plan and then implement that corrective action plan expeditiously.
At the end of the inspection, the company was issued a Form 483 with six observations. The Company will respond to the US FDA within the stipulated timeline and work closely with US FDA to close the observations
Subscribe to PharmaTutor News Alerts by Email
